Research programme: DNA-based monoclonal antibody therapeutics - Inovio Pharmaceuticals

Drug Profile

Research programme: DNA-based monoclonal antibody therapeutics - Inovio Pharmaceuticals

Alternative Names: BEAT-HIV programme

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Inovio Pharmaceuticals; MedImmune; Wistar Institute
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Chikungunya virus infections; HIV infections; Influenza virus infections; Pneumonia; Prostate cancer

Most Recent Events

  • 21 Sep 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 21 Sep 2017 Preclinical trials in Pneumonia (Prevention) in USA (Parenteral)
  • 21 Sep 2017 Inovio Pharmaceuticals plans a phase I trial for Ebola virus infections in 2018 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top